Many studies have reported that the PI3K-AKT-mTOR pathway is active in various tumors, and related drugs such as PI3K, AKT, and mTOR inhibitors have been used in the clinical treatment of DLBCL [38–40]. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.